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For several decades, apoptosis has taken center stage as the principal mechanism of programmed cell death (type I cell death)
in mammalian tissues. Autophagic cell death (type II) is characterized by the massive accumulation of autophagic vacuoles in the
cytoplasmofcells.Theautophagicprocessisactivatedasanadaptiveresponsetoavarietyofextracellularandintracellularstresses,
including nutrient deprivation, hormonal or therapeutic treatment, pathogenic infection, aggregated and misfolded proteins, and
damaged organelles. Increasing evidence indicates that autophagy is associated with a number of pathological processes, including
cancer. The regulation of autophagy in cancer cells is complex since it can enhance cancer cell survival in response to certain
stresses,whileitcanalsoacttosuppresstheinitiationofcancergrowth.Thispaperfocusedonrecentadvancesregardingautophagy
in cancer and the techniques currently available to manipulate autophagy.
1.Introduction
Current cancer therapies are based on the surgical removal
of solid tumor masses, usually combined with a series of
chemical (chemotherapy) or physical (radiotherapy) treat-
ments; however, chemotherapy has reached a plateau of
eﬃcacy as a treatment modality with the emergence of
resistant tumors. Despite the wide variety of mechanisms,
most new drugs are thought to ultimately induce apoptosis
of tumor cells through mitochondrial and/or death-receptor
pathways, although these pathways are often defective in
cancer. More recently, other mechanisms of cell death have
emerged as potential novel mechanisms for cancer therapies
t oi n d u c ec e l ld e a t h .
Macroautophagy (hereafter referred to autophagy) is a
eukaryotic, evolutionarily conserved homeostatic process in
whichorganellesandbulkproteinsareturnedoverbylysoso-
mal activity [1]. Autophagy and apoptosis may be intercon-
nectedandevensimultaneouslyregulatedbythesametrigger
in tumor cells. In periods of metabolic stress, autophagy
provides ATP and other macromolecules as energy sources
toenablecellsurvival;however,iftheintensityordurationof
metabolic stress is excessive, cells may progress to autophagic
programmed cell death, which is distinct from apoptosis [2].
In contrast, whether autophagy contributes to the antitumor
eﬀect of chemotherapeutic drugs or to drug resistance is
largely unknown. In addition, there is no current consensus
on how to manipulate autophagy to improve clinical out-
comes. This paper describes the role of autophagy with a
particular focus on the roles of cytoplasmic organelles and
presents newly recognized approaches to pharmacologically
exploitthesemechanismsforimprovedantitumoroutcomes.
2.Autophagy Networks
2.1.DegradationSystem. Eukaryoticcellsrespondtochanges
in their environment and the intracellular milieu by alter-
ing their anabolic and catabolic pathways. As one of the
responses,livingorganismsfromyeasttohumansarecapable
of eating parts of themselves in order to survive. The so-
called autophagy is a self-degradative process which ensures
the regular turnover of cellular components by sequester-
ing damaged organelles and misfolded proteins, targeting
them for lysosomal degradation [3]. While the ubiquitin-
proteasomal system is generally used for the degradation of2 International Journal of Cell Biology
short-lived proteins, autophagy degrades and recycles long-
lived proteins and organelles. After its discovery, autophagy
was considered a kind of disposal mechanism aimed at
recycling of cellular components [4], but now autophagy is
implicated in more diverse physiological processes such as
development, proliferation, remodeling, aging, tumor sup-
pression, neurodegeneration, antigen presentation, innate
immunity, regulation of organismal lifespan, and cell death
[5]. In most of these situations, autophagy has both ben-
eﬁcial and harmful eﬀects on cell functions. One aspect of
this complexity probably reﬂects the dual role of autophagy,
whichisbothcell-protectiveand-destructive.Autophagycan
be a survival response in situations of stress, allowing the
eliminationoftoxicmetabolites,intracellularpathogens,and
damaged proteins and organelles and providing energy and
amino acids necessary for vital functions during metabolic
stress; however, in some sense the induction of excessive
autophagy can lead to cell death. In addition, autophagy
provides signals for removal of apoptotic cells and genomic
stability [6]. Hence, autophagy can be generally considered
as a cell protector against various types of injuries or
continuous cellular wear and tear and is expected to play a
protective role in diverse types of cellular stress. Paradoxi-
cally, autophagy can also lead to a form of nonapoptotic cell
death, which is called type II programmed cell death [7].
Thus, autophagy could either promote cell death or protect
cells from diverse types of injuries depending on the cellular
and environmental context.
2.2. Signaling System. The serine/threonine kinase, mam-
malian target of rapamycin (mTOR), is a major negative reg-
ulatorofautophagy.Thephosphoinositide3-kinase-(PI3K-)
activated serine/threonine kinase Akt phosphorylates the
mTOR repressor TSC2 (tuberous sclerosis complex 2), thus
leading to activation of mTOR and subsequent blockade of
expressionandfunctionofautophagy-inducingAtgproteins.
In addition to Akt, one of the main mTOR regulators is
AMP-activated protein kinase (AMPK), a principal energy-
sensing intracellular enzyme activated in various cellular and
environmental stress conditions. In response to increases in
AMP/ATP ratio, AMPK preserves energy by switching oﬀ
ATP-requiring processes, while switching on ATP-generating
catabolic pathways. AMPK maintains energy homeostasis by
inducing autophagy and blocking protein synthesis and cell
proliferation mainly through phosphorylation of its down-
stream target Raptor and consequent inhibition of mTOR.
In addition to a major role of the AMPK/mTOR pathway
in regulation of intracellular and whole body metabolism,
recent ﬁndings point to its potential involvement in con-
trolling proliferation, survival, and death of cancer cells
[8]. Namely, pharmacological activation or overexpression
of AMPK in a variety of cancer cell types caused an mTOR
inhibition-associated cell cycle arrest and apoptotic death
both in vitro and in vivo [9]. On the other hand, AMPK
activity in certain conditions protected normal and cancer
cells from metabolic stress and/or chemotherapy-induced
apoptosis[10].Autophagicdigestionofintracellularproteins
triggered by mTOR-downregulation in tumor cells seems to
play an important role both in AMPK-mediated cytotoxicity
and cytoprotection [11, 12], the ﬁnal outcome possibly
depending on the nature of the cytotoxic stimulus. The
physiological role of autophagy in the mammalian system
has been shown in several in vivo animal models. Disruption
of the autophagic process leads to failure of cavitation during
embryogenesis or accumulation of abnormal organelles such
as mitochondria or endoplasmic reticulum (ER) in adult
tissues [13, 14]. In addition to the physiological roles, dys-
regulated autophagy has been suggested to play pathogenetic
roles in a variety of disease processes, particularly when
cellular stress is increased, which is probably because of the
accumulation of damaged molecules and organelles. It has
been suggested that the role of autophagy in degenerative
changes is associated with ageing or diverse degenerative
disorders [15].
3.ProgrammedCellDeath
The term programmed cell death refers to controlled or
regulated forms of cell death associated with a series of
biochemical and morphological changes. Programmed cell
death is an evolutionarily conserved process to decide cell
fate, which has therefore been drawing increasing attention
in cancer treatment. Programmed cell death can be divided
intoseveralcategories:typeI(apoptosis),typeII(autophagic
cell death), and others (necrosis, senescence, and mitotic
catastrophe).
3.1. Type I Programmed Cell Death. In type I, the typical
morphology of apoptosis is largely the end result of caspase-
mediated destruction of the cellular structure [16]. There
are two core pathways inducing apoptosis: the extrinsic and
intrinsic pathways. The extrinsic pathway is triggered by
the Fas death receptor (DR), which is mainly dependent
on the initiation of the combination between FasL and
Fas. The intrinsic pathway is another process leading to
apoptosis, in which mitochondria play a central role. When
cells sense extracellular stimuli or intracellular signals,
the outer mitochondrial membrane becomes permeable,
releasing cytochrome c. The ER, lysosomes, and the trans-
Golgi-network also play important roles [17]. Each organelle
possesses sensors that detect speciﬁc alterations, locally
activate signal transduction pathways, and emit signals that
ensure interorganellar cross-talk. It is often assumed that
apoptosis is initiated if the damage is too severe to be
repaired, or if the time-scale for complete repair is too long.
3.2. Type II Programmed Cell Death. Autophagy has been
associated with a particular mode of cell death that is charac-
terized by the appearance of double- or multiple-membrane
cytoplasmic vesicles engulﬁng bulk cytoplasm and/or cyto-
plasmic organelles such as mitochondria and ER; however,
many studies failed to demonstrate a causal link between
autophagy and cell death. Autophagy is probably not an
executor of cell death per se, but it is a required process in
certain settings in combination with other prodeath signals.
Cells undergoing autophagic cell death were engulfed byInternational Journal of Cell Biology 3
human macrophages as well as vital cells [18]. To distinguish
it from apoptosis (type I cell death), this has been termed
autophagic or type II cell death [19]. The machineries for
apoptosis, autophagy, and necrosis (type III cell death) are
interconnected and somehow coordinated between the two.
For example, the elimination of damaged mitochondria
by autophagy would prevent the release of proapoptotic
substances from mitochondria, thus preventing apoptosis.
In the absence of such clean up, the release of molecules
like cytochrome c and apoptosis-inducing factor (AIF) from
damaged mitochondria would lead to apoptosis and in the
case of extreme damage and ATP depletion, to necrotic cell
death.
4. Autophagy in Cancer
There is an accumulation of evidence that highlights the
important function of autophagy in cancer. Although it is
still controversial as to whether autophagy kills cancer cells
or sustains their survival under stressful conditions, more
reports provide data to support that autophagy promotes
cancer cell survival after chemotherapy or radiation therapy
[20].Thehighrateofautophagyobservedinundiﬀerentiated
colon cancer cells is compatible with the expression of
Beclin 1 and PTEN (phosphatase and tensin homolog) in
these cells. Cancer cells are frequently exposed to inherent
metabolic stress owing to hypoxia and lack of nutrient
supplies. Hypoxia-inducible factor 1α (HIF-1α) ,ak e yt r a n -
scription factor encoding a plethora of genes responsible
for altered metabolism, angiogenesis, invasion, metastasis,
or therapy-resistance in hypoxic tumors [21], is a positive
regulator of autophagy. Small-interfering-RNA- (siRNA-)
mediated depletion of Atg proteins sensitizes cancer cells to
radio- and chemotherapy, and the autophagy inhibitors 3-
methyladenine(3-MA)andbaﬁlomycinA1causeradiosensi-
tization of malignant glioma cells [20]. Thus, cancer was one
of the ﬁrst diseases genetically linked to impaired autophagy.
The tumor-suppressive role of autophagy was ﬁrst
shown in mice heterozygous for the Beclin 1 autophagy
protein. These mice (beclin 1+/−) showed reduced autophagy
and increased cellular proliferation, which translated into
increased incidence of spontaneous malignancies, such as
lymphomas, lung, and liver cancers [22]. Incidentally, beclin
1
−/− mutant mice died early in embryonic development.
Liang et al. reported beclin 1 as a potential tumor suppressor
gene, the expression of which is frequently decreased in
human breast epithelial carcinoma cell lines and tissue com-
pared to the higher level in normal tissue [23]. Low expres-
sion of Beclin 1 in 115 node-positive colon cancer specimens
was associated with a signiﬁcantly worse 5-year overall
survival (47% versus 67%) [24]. The PI3K/Akt/mTOR axis
plays a decisive role in the negative regulation of autophagy,
and the constitutive activation of this pathway has been
implicated in many human cancers [25]. Autophagy is
thought to mediate Sqstm1/p62 elimination and to suppress
tumorigenesis; however, defective autophagy allows overex-
pression of p62 that promotes tumorigenesis. The sustained
p62 overexpression in tumor cells with defective autophagy
appears to dysregulate NF-κB signaling, and altered NF-κB
regulation resulting from p62 overexpression is proposed
to be a primary mechanism for enhancing tumorigenesis
[26]. Persistent DNA damage induced by the increased
levels of reactive oxygen species (ROS), which are associated
with the accumulated mutant proteins and dysfunctional
mitochondria found in autophagy-deﬁcient tissues, is also
proposed as a causative link between autophagy inhibition
and enhanced tumor formation [27]. Thus, the inability
of autophagy-defective tumor cells to eliminate p62 con-
tributes to oxidative stress and likely to DNA damage. These
observations suggest that autophagy is important for tumor
suppression.
Ultimately, autophagy in cancer has diﬀerent eﬀects in
diﬀerent ways in diﬀerent cancer cell lines at diﬀerent stages
of tumorigenesis and progression. The early stages of tumor
development require cancer cells to undergo a higher level of
protein synthesis than protein degradation for the tumor to
grow. Thus, autophagy probably functions to prevent cancer
initially, but once a tumor develops, the cancer cells utilize
autophagy for their own cytoprotection. Elucidating this
complex physiological process is crucial for development of
anticancer therapies with maximum eﬃcacy and minimum
drug resistance.
5. Cross-Talk betweenApoptosis
and Autophagy in Cancer
Expandingourknowledgeofthemolecularcross-talkamong
pathways that regulate tumor cell death is crucial in guiding
the successful design of future anticancer therapeutics. In
particular, apoptosis and autophagy can act as partners to
induce cell death in a coordinated or cooperative fashion.
Autophagy proteins can also play a role in cellular events
that occur during apoptosis. For example, Atg5 may be an
independent key player in both apoptosis and autophagy.
The low levels of Atg5 cleavage product may have signiﬁcant
eﬀects on apoptosis, but not the intact Atg5 that participates
in autophagy [28]. Bcl-2 phosphorylation may not only be
a mechanism for regulating apoptosis and a mechanism for
regulating autophagy, but perhaps also a mechanism for
regulating the switch between the two pathways [29]. JNK
(c-Jun NH2-terminal kinase) is able to trigger autophagy by
targeting Bcl-2/Bcl-xL proteins and abrogating their binding
to Beclin 1. Recently, Beclin 1 has been shown to be among
the substrates of death-associated protein kinase (DAPK), a
proapoptotic serine/threonine kinase, and its phosphoryla-
tion reduces its binding to the Bcl-2 family members, thus
suggesting a possible mechanism by which DAPK may also
induce autophagy [30]. A complex role in the regulation
of autophagy is played by p53, one of the most important
tumor suppressor proteins. In fact, p53 regulates autophagy
both in a positive and in a negative fashion, depending on
its subcellular localization [31]. p53 and DRAM (damage-
regulated autophagy modulator) can induce accumulation
of autophagosomes. In addition, p53 aﬀects autophagy by
modulating signaling through the mTOR nutrient-sensing
kinase which controls autophagy at the initiation stage [32].4 International Journal of Cell Biology
Inhibition of autophagy leads in most cases to an increase
susceptibility to apoptotic stimuli. Moreover, a growing
number of proteins that play a negative regulatory role
in both events have been identiﬁed [33]. Autophagy and
apoptosis may be triggered by common upstream signals.
Recent reports have shown that Akt inhibits apoptosis by
phosphorylation of the Bcl-2 protein family member, Bad,
allowing for cell survival. In addition, activation of the
PI3K/Akt/mTOR pathway can cause inhibitory eﬀects of Akt
on apoptosis and mTOR on autophagy and enhance survival
capacity in neoplastic cells [34].
In addition, several Atg proteins, including Atg5 and
Beclin 1 (Atg6), can be cleaved by calpain or caspases that are
activated during apoptosis [35]. Caspase-dependent cleavage
of Beclin 1 occurred in HeLa cells treated with a death recep-
torligand[36].Chemotherapy-inducedapoptosissuppresses
autophagy at the execution stage following cytochrome c
release, at least in part through caspase 8-mediated cleavage
of Beclin 1 at Asp133 and Asp146 [37]. Caspase 3 cleaved
Beclin1atAsp149 inapoptosisinducedbyBaxoverexpression
[38]. Caspase-9 can also cleave Beclin 1, thereby destroying
its proautophagic activity [39]. Moreover, the C-terminal
fragment of Beclin 1 that results from this cleavage acquires a
new function, which can amplify mitochondrion-mediated
apoptosis. These ﬁndings provide important insights into
the molecular cross-talk between autophagy and apopto-
sis. Apoptosis can begin with autophagy, which can end
with apoptosis. Some links between the two types of
cell death are indicated via mitochondria. Induction of
mitochondrial membrane permeabilization at a low level,
below the threshold required for induction of apoptosis,
results in sequestering damaged mitochondria in autophagic
vacuoles. When mitochondrial membrane permeabilization
is suﬃciently high to sustain the active execution of cell
death, apoptosis is induced [40]. Therefore, it is likely that
induction of apoptotic or autophagic cell death may depend
on the level of mitochondrial membrane permeabilization.
6. ERand Autophagy
ER is an essential intracellular organelle providing apparatus
for synthesizing nascent proteins as well as their further
modiﬁcation and correct folding, such as the formation of
N-linked glycans and disulphide bonds. Disruption of any of
these processes, such as with glucose depletion that prevents
the proper glycosylation of proteins or with alterations in
calcium homeostasis such that calcium-dependent chaper-
ones cannot function properly, leads to the accumulation
of misfolded proteins that triggers ER stress. ER stress has
been implicated in diﬀerent stages of tumor development.
The ER has by now been established as an essential site
for the regulation of apoptotic pathways and has recently
been recognized as an important component of autophagic
signaling. ER stress appears to signal autophagy by pathways
that all depend on eIF2α (eukaryotic initiation factor 2α).
How eIF2α regulates autophagy is presently unknown, but
the induction of Atg12 expression via ATF4 (activating
transcription factor 4) is likely to participate in this process.
In cancer cells, when the amount of unfolded or misfolded
proteins exceeds the capacity of the proteasome-mediated
degradation system, autophagy is triggered to remove these
proteins.
Bcl-2hasbeenmainlystudiedinthecontextofcelldeath,
but it is also known to carry out other functions in dif-
ferent cellular processes, such as cell cycle progression, glu-
cose homeostasis, transcriptional repression by p53, and
autophagy. Beclin 1 has been identiﬁed as a novel BH3- (Bcl-
2-homology-3-) only protein. Beclin 1 induces autophagy by
promotingautophagosomeformationwhenincomplexwith
hVps34 (vacuolar protein sorting 34)/class III PI3K. Beclin
1-Bcl-2 (Bcl-xL) complexes normally inhibit autophagy,
which points to organelle-speciﬁc regulation of autophagy
[41]. Beclin 1 binding with Bcl-2 has been suggested to
interfere with the ability of Beclin 1 to form a complex with
hVps34/PI3K, thus resulting in a loss of Beclin 1-associated
PI3K autophagy-inducing activity. The interaction between
Beclin 1 and Bcl-2 is abolished when key residues within the
BH3 domain of Beclin 1 or the BH3-binding groove of Bcl-
2 are mutated. ER-localized Bcl-2, but not mitochondria-
localized Bcl-2, has been shown to be important for the
inhibition of autophagy [42]. The ER functions to synthesize
proteinsthatstorehighintracellularcalciumthatcanactivate
calcium-dependent chaperone proteins that assist in protein
folding. The autophagy inhibition by Bcl-2 is evident only
when Bcl-2 resides in the ER, where it has been suggested to
regulate cellular Ca2+ homeostasis. Ca2+ regulates autophagy
via a signaling pathway involving AMPK and mTOR, and
ER-located Bcl-2 eﬀectively inhibits this pathway. ER-located
Bcl-2 inhibits autophagy induced by Ca2+ mobilizing agents
byregulatingtheCa2+ homeostasisinaBeclin1-independent
manner [43].
7. Golgi andAutophagy
Eukaryotic cells possess an internal endomembrane system
that compartmentalizes the cell for various diﬀerent cellular
functions. The main components of this membrane system
are the ER, Golgi complex, vesicles, plasma membrane,
vacuole/lysosome, and nuclear envelope. Autophagy dis-
plays unique membrane dynamics, distinct from classical
membrane traﬃcking. The Golgi complex is required for
double-membrane cytoplasm to vacuole targeting vesicle
and autophagosome formation. A number of Rab GTPases
which regulate secretory and endocytic membrane traf-
ﬁc have been shown to play either critical or accessory
roles in autophagy. Rab33B, a member of the Rab small
GTPase family, which was originally described as a Golgi-
resident protein involved in Golgi-to-ER transport [44],
directly interacts with an autophagosome precursor marker,
Atg16L, in a GTP-dependent manner, and the activation
and inactivation of Rab33B modulate autophagy. Based on
these results, the possible role of the interaction between
Rab33B and Atg16L was suggested in autophagosome
formation [45]. The autophagosomes are not formed by
Golgi-derived vesicles/membranes alone because single-
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and autophagosome membranes are composed of mem-
b r a n e sd e r i v e df r o mr o u g hE R .E Ra n dG o l g ic o m p l e x -
derived vesicles could be delivered to the lysosome/vacuole
by a pathway that is diﬀerent from canonical autophagy.
Under certain conditions, these two organelles might not
requiresequestrationbyadoublemembranefordeliveryand
subsequent degradation. Furthermore, it has been reported
that one of the Atg proteins, Atg9, a membrane protein
with unknown function, shuttled between the trans-Golgi
network and late endosomes. Bax-interacting factor 1 (Bif-
1) binds the proapoptotic Bcl-2 family protein Bax. Bif-1
overexpression promotes Bax activation and apoptosis. Bif-1
also regulates the ﬁssion of Golgi membranes and the traf-
ﬁcking of Atg9 from the Golgi complex to autophagosomes
during starvation [46]. Therefore, isolation membranes and
autophagosome membranes may be made up of membranes
from several diﬀerent sources, including the Golgi; however,
there is little evidence that the Golgi complex contributes
directly to the formation of the autophagic membrane.
8. Mitochondria and Autophagy
Mitochondria are key players in several cancer cellular func-
tions, including growth, division, energy metabolism, and
apoptosis, and play a central role in cell survival and death.
Mitochondriaalsoplayanimportantroleintheformationof
autophagosome and its subsequent docking and fusion with
lysosome and could contribute to the increased autophagy
and autophagic ﬂux in metastatic cancer. The ability of
tumor mitochondria to increase autophagy may help cancer
cells to fulﬁll high anabolic needs during rapid growth;
however, mitochondrial functions (such as respiration) can
block autophagic cell death [47]. Autophagy often occurs
when the mitochondria fail to maintain ATP levels, during
starvation, or when the mitochondria are damaged. A
process known as mitophagy selectively eliminates the dam-
aged mitochondria. Furthermore, blocking mitochondria-
mediated apoptosis through the elimination of mouse Bax
and Bak (Bak1) expression promotes autophagy-induced
cell death. Arsenic-trioxide- (As2O3-) induced cell death
in human malignant glioma cell lines was accompanied
by involvement of an autophagy-speciﬁc marker, LC3,
and damage to mitochondrial membrane integrity. Arsenic
trioxide induces the mitochondrial localization of the pro-
cell-death Bcl-2 family member BNIP3 (Bcl-2/adenovirus
E1B 19-kDa protein-interacting protein 3), which deter-
mines the on/oﬀ state of the mitochondrial permeability
transition (MPT) pore [48]. The reciprocal relationship
between mitochondrial metabolism and the activity of the
rapamycin-sensitive pathway has been described before [49].
Mitochondria dysfunction leads to inhibition of mTOR,
and inactivation of p70S6K (ribosomal protein S6 kinase)
results in dephosphorylation of Bad, potentially leading to
increased interaction between Bad and Bcl-xL or Bcl-2, to
mitochondrial damage and cell death [50]. In addition, the
promotion of MPT also contributed to increased autophagy.
These results suggested that mitochondria from a highly
metastatic breast cancer cell line can promote homeostatic
autophagy of cancer by opening low-conductance MPT
pores. The activation of autophagy by tumor mitochondria
was reduced by cyclosporine A, which is an inhibitor that
blocks the low-conductance state of MPT pores [47]. ROS
could be the mediator leading to the loss of mitochondria
membrane potential, possibly by triggering the opening of
theMPTporethatsubsequentlyleadstocelldeath.ROSwere
recently shown to activate starvation-induced autophagy,
antibacterial autophagy, and autophagic cell death. Short-
chain fatty acids were shown to induce ROS production,
which led to AMPK activation and consequential mTOR
inhibition [51]. Current ﬁndings implicate ROS in the regu-
lationofautophagythroughdistinctmechanisms,depending
on the cell type and stimulation conditions; conversely,
autophagy can also suppress ROS production.
9. ExperimentalManipulation of Autophagy
For a better understanding of the regulation of autophagy,
many studies have used chemical modulators of autophagy:
inhibitors and inducers. The diﬀerent modulators are an
important tool in studying the functions of autophagy,
although it is diﬃcult to deﬁne the mechanism closely.
Appropriate modiﬁcation of autophagy, that is, inhibi-
tion of cytoprotective autophagy or promotion of cyto-
killing autophagy could mitigate the cytotoxicity caused by
anticancer therapy in tumor cells.
9.1. ProAutophagics (Table 1)
9.1.1. Beclin 1. The mechanism by which a small molecule
Bcl-2/Bcl-xL antagonist ABT-737 can potentiate autophagy
may be related to its ability to competitively disrupt the
binding of Bcl-2/Bcl-xL to the autophagic protein Beclin 1
(Atg6) [52]. Treatment with fenretinide (RT-101), a synthetic
derivative of retinoic acid, resulted in an increase in Beclin
1 expression, the conversion to the form LC3-II form,
and its shift from diﬀuse to punctate staining and ﬁnally
an increase in lysosomes/autophagosomes [53]. In addi-
tion, HIF-1α is required for fenretinide-induced protective
autophagy under hypoxia. The inositol 1,4,5-trisphosphate
receptor (IP3R) antagonist xestospongin B induces autophagy
by disrupting a molecular complex formed by IP3Ra n d
Beclin 1. Xestospongin B-induced autophagy was inhibited
by overexpression of the IP3R ligand-binding domain, which
co-immunoprecipitated with Beclin 1 [54]. Autophagy can
be generally induced via several distinct pathways, such as
inhibition of mTOR or activation of Beclin 1. Okadaic acid,a
protein phosphatase 2A inhibitor, increased both the mTOR
and Beclin 1 pathways simultaneously, which suggests that
autophagy in okadaic acid-treated neurons is induced mainly
via the Beclin 1 pathway, and less so via mTOR inhibition
[55].
9.1.2. DNA Damage. Exogenous environmental agents such
as ultraviolet (UV) and ionizing radiation, genotoxic chem-
icals, and endogenous byproducts of metabolism, including
ROS, cancausealterationsin DNAstructure(DNAdamage).6 International Journal of Cell Biology
Table 1: Proautophagics.
Class (target) Compounds Autophagic mechanisms Reference
Beclin 1
ABT-737
Fenretinide
Xestospongin B
Okadaic acid
Disruption of Bcl-2/Bcl-xL binding to Beclin 1
Increase in Beclin 1 expression
Disruption of the complex formed by IP3R and Beclin 1
Increase in Beclin 1 pathways
[52]
[53]
[54]
[55]
DNA damage
UV
ROS
Camptothecin
p53 activation
PTEN upregulation
mTOR suppression
[56]
ER stressors
A23187
Thapsigargin
Tunicamycin
Brefeldin A
Bortezomib
Sorafenib
GRP78 induction
Increase of Ca2+ in cytosol
PERK/elF2α pathway
Induction of GRP78 and GRP94
Unfolded protein response
Inhibition of mTOR signaling
[57]
[58]
[59]
Farnesyltransferase
inhibitors
Manumycin A
FTI-276
Lonafarnib
Akt downregulation and mTOR phosphorylation [60]
Golgi-associated agents Brefeldin A
Paclitaxel
Interruption of traﬃcking of N-linked glycoproteins
Fragmentation of Golgi apparatus
[61]
[62]
HDAC inhibitors
SAHA
Valproic acid
FK228
Downregulation of Akt and mTOR activity
Increase in mitochondrial ROS
Nuclear translocation of AIF
[63]
[64]
[65]
[66]
Mitochondrial agents Selenite
Resveratrol
Degradation of mitochondrial proteins
Inhibition of mitochondrial function
[7]
[67]
mTOR inhibitors
Rapamycin
Berberine
Torin1
Ku-0063794
PM02734
mTORC1 inhibition
Akt suppression and p38 MAPK upregulation
Inhibition of mTORC1 and mTORC2
Dephosphorylation of mTORC1 substrate 4E-BP1
DAPK activation
[68]
[69]
[70]
[71]
[72]
Pathogens Bacteria
HSV-1
Ubiquitin-p62-NDP52 pathway
PKR and eIF2α activation
[73]
[74]
Proteasome inhibitors MG-132
Glidobactin A
ER stress induced by misfolded proteins
Catalytic subunits of 20S proteasome
[75]
[76]
DNA damage induces autophagy, but its role in the DNA
damage response is still unclear. Recent reports using the
DNA-damaging agents, camptothecin, etoposide (VP-16),
tomozolomide,a n dp-anilioaniline (p-aminodiphenylamine),
demonstrate that cells, in addition to initiating cell cycle
arrest, also initiate autophagy. p53 is a central regulator of
apoptosis induced by DNA damage. Interestingly, p53 is
a bidirectional regulator of autophagy. p53 activation also
leads to upregulation of the PTEN, an inhibitor of the
PI3K/Aktsignalingpathway,andTSC2,atthetranscriptional
level, which may contribute to the long-term suppression of
mTOR [56].
9.1.3. ER Stressors. Autophagy was induced by chemicals,
such as A23187, tunicamycin, thapsigargin,a n dbrefeldin A
that cause ER stress [57]. The calcium ionophore A23187
induced the expression of BiP/GRP78 protein, which is an
ER stress marker protein. GRP78, through maintenance of
ER structure and homeostasis, facilitates autophagy. Dis-
turbances in normal ER processes lead to an evolutionarily
conserved cell stress response, referred to as the unfolded
protein response (UPR). Tunicamycin, an inhibitor of N-
glycosylation, is a potent stimulator of ER stress. The link
between tunicamycin-induced ER stress and autophagy was
the PERK/elF2α pathway. Thapsigargin, an inhibitor of the
ER calcium transporters, generates Ca2+-store depletion
within the ER and simultaneously increases the Ca2+ level
in the cytosol. Brefeldin A (an inhibitor of vesicle transport
between the ER and Golgi) can increase the expression
of both glucose-regulated proteins GRP78 and 94, which
disrupt some functions of the ER. The inhibition of the
26S proteasome by the dipeptide boronic acid bortezomib
(velcade) leads to the accumulation of misfolded proteins,
resulting in ER stress followed by a coordinated cellular
UPR response [58]. Induction of autophagy by bortezomib
is dependent on the proteasomal stabilisation of ATF4 and
upregulation of LC3B by ATF4. Sorafenib (nexavar), a potent
multikinase inhibitor, inhibited phosphorylation of Stat3
and expression of cyclins, D and E, and exerted signiﬁcant
antitumor activity through inhibition of mTOR signaling. In
addition, sorafenib induced autophagy in human hepatocel-
lular carcinoma cells through mechanisms that involved ERInternational Journal of Cell Biology 7
stress and was independent of the MEK1/2-ERK1/2 pathway
[59].
9.1.4. Farnesyltransferase Inhibitors. Farnesylation is a post-
translational modiﬁcation of proteins in which farnesyl-
transferase catalyzes the attachment of the isoprenoid group
from farnesyl pyrophosphate to a cysteine residue at the
C-terminus of proteins. The farnesyltransferase inhibitors
manumycin A, FTI-276,a n dlonafarnib (sarasar) induced
autophagy in human cancer cell lines [60]. Treatment with
a combination of oridonin and manumycin A (a natural
product of Streptomyces parvulus) downregulated phospho-
rylation of Akt, downstream of PI3K. Oridonin triggers
apoptosis of cancer cells and is partially eﬀective through
mitochondrial depolarization. Lonafarnib decreased phos-
phorylation of mTOR and S6 kinase, which is downstream
of mTOR, in a dose-dependent manner. FTI-276 is a CAAX
peptidomimetic of the carboxyl terminal of Ras proteins.
FTI-276 was identiﬁed as a highly selective suppressor of
Ras-dependent oncogenicity, and FTI-276 inhibited Akt
phosphorylation.
9.1.5. Golgi-Associated Agents. Brefeldin A inhibits the acti-
vation and membrane-binding properties of most ADP-
ribosylation factors and causes the redistribution of Golgi
proteins into the ER. Brefeldin A leads to dramatic changes in
the structure of the Golgi apparatus causing the conversion
of the staked cisternae into vesicular/cisternal remnants.
Brefeldin A even when acting alone, increases the volume
fraction of autophagic vacuoles. The destabilization of the
Golgi apparatus by brefeldin A interrupts the intracellular
traﬃcking of N-linked glycoproteins along the secretory
pathway [61]. Treatment of cells with paclitaxel (taxol)
results in polymerization of microtubules. After incubation
with paclitaxel, the Golgi apparatus is fragmented and is
conspicuously present in areas of the cytoplasm enriched
in microtubules. Paclitaxel treatment could lead to the
formation of acidic vesicular organelles, the induction of
Atg5, Beclin 1, and LC3 expressions, and an increase in
punctate ﬂuorescent signals in A549 cells pretransfected with
GFP-tagged LC3 [62].
9.1.6. HDAC Inhibitors. Histone acetylation is mediated by
histone acetyltransferases and deacetylases (HDACs), which
inﬂuence chromatin dynamics, protein turnover, and the
DNA damage response. The HDAC inhibitor SAHA (sub-
eroylanilide hydroxamic acid, vorinostat) can induce both
caspase-dependentapoptosisandcaspase-independentauto-
phagic cell death, so it has clear therapeutic implications
[63]. SAHA induced autophagy through downregulation of
Akt/mTORsignalingandinductionoftheERstressresponse.
Moreover, SAHA treatment upregulated expression of Beclin
1 and Atg7 and promoted formation of the Atg5-Atg12 con-
jugate [64]. Valproic acid was identiﬁed as a potent selective
histone deacetylase inhibitor, which induces autophagy in
glioma cells. Valproic acid is capable of producing elevated
levels of mitochondrial ROS in glioma cells. ROS production
results in autophagosome development and autolysosomal
degradation [65]. FK228 (romidepsin) is a unique cyclic
peptide and is among the most potent inhibitors of both
Class I and II HDACs. FK228 converted LC3-I to LC3-II
and induced localization of LC3 to autophagosomes. FK228-
mediated autophagy in rhabdomyosarcoma cells coincided
with nuclear translocation of AIF, while knockdown of AIF
abrogated autophagy following FK228 exposure [66].
9.1.7. Mitochondrial Agents. An essential trace element,
selenite, is preferentially cytotoxic to various human glioma
cells over normal astrocytes via autophagic cell death.
Before selenite-induced cell death in glioma cells, disruption
of the mitochondrial cristae, loss of mitochondrial mem-
brane potential, and subsequent entrapment of disorganized
mitochondria within autophagosomes or autophagolyso-
somes, along with degradation of mitochondrial proteins,
were noted, showing that selenite induces autophagy in
which mitochondria serve as the main target [7]. The
phytoalexin resveratrol (trans-3,5,4 -trihydroxystilbene), a
defensive substance produced by plants in response to
infection by pathogenic microorganisms, displays a wide
range of biological eﬀects in mammalian cells. Resveratrol
induced autophagy through any of numerous mechanisms
that involve activation of mitochondria, downregulation of
cell survival proteins, inhibition of cell survival kinases, and
survival transcription factors [67].
9.1.8. mTOR Inhibitors. Rapamycin (sirolimus) and its ana-
logues (such as CCI-779, RAD001,a n dAP23573) inhibit
mTOR (mTORC1), the kinase that normally suppresses
both apoptosis and autophagy. Rapamycin activates the
autophagic process, and silencing of mTOR with siRNA
increases the inhibitory eﬀect of rapamycin on tumor cell
viability by stimulating autophagy [68]. Berberine, a small
molecule derived from Coptidis rhizome, can induce both
autophagy and apoptosis in hepatocellular carcinoma cells.
Berberine may also induce autophagic cell death in HepG2
and MHCC97-L cells through activation of Beclin 1 and
inhibition of the mTOR-signaling pathway by suppressing
the activity of Akt and upregulating p38 MAPK signaling
[69]. Treatment with torin1 signiﬁcantly enhanced lysosomal
accumulation of mTOR and Raptor. Torin1 inhibits mTOR
by directly competing with ATP for binding to the kinase
domain. Thus, torin1 inhibits both mTORC1 and mTORC2
[70]. The small molecule Ku-0063794, which inhibits both
mTORC1 and mTORC2 with an IC50, induced a much
greater dephosphorylation of the mTORC1 substrate 4E-
BP1 (eukaryotic initiation factor 4E-binding protein 1) than
rapamycin [71]. PM02734 (elisidepsin) causes cell death by a
complex mechanism that involves increased autophagosome
content, due for the most part to impairment of autophagic
ﬂux, inhibition of the Akt/mTOR pathway, and activation
of DAPK. This unique mechanism of action justiﬁes the
continued development of this agent for the treatment of
lung cancer [72].
9.1.9. Pathogens. Autophagy has recently emerged as an im-
portant mechanism for controlling intracellular pathogens.8 International Journal of Cell Biology
A variety of diﬀerent bacteria, including Mycobacte-
ria, Salmonella, Shigella,a n dListeria, are recognized by
autophagy,yetthespeciﬁcsignalsthatmediaterecognitionof
intracellularpathogensbytheautophagymachineryhavenot
been deﬁned thus far. It is currently thought that ubiquitin
associated with intracellular pathogens promotes targeted
autophagosome formation and pathogen destruction. In
addition, p62 and NDP52 mediate diﬀerent pathways of
selective autophagy for Shigella and Listeria and provide
novelinsightintothemechanismsbywhichadaptorproteins
target bacteria to autophagy [73]. Infection with Herpes
simplexvirustype1(HSV-1)provokedautophagyundercon-
ditions that inhibited viral gene expression. The induction
of autophagy occurs very early after infection with HSV-
1,a n dde novo protein synthesis is not required for the
response [74]. Autophagy can be induced by the presence of
foreign DNA within cells. The interferon-inducible, dsRNA-
dependent protein kinase R (PKR) plays an important role
in innate immunity against viral infections. PKR activation
leads to phosphorylation of eIF2α and a subsequent shut-
downofhostandviralproteinsynthesisandviralreplication.
PKR and eIF2α phosphorylation regulate another funda-
mental cellular process, the lysosomal degradation pathway
of autophagy.
9.1.10. Proteasome Inhibitors. The ubiquitin-proteasome
system and lysosome-dependent autophagy are two major
intracellular pathways for protein degradation. The ubiq-
uitin-proteasome pathway is a novel therapeutic target for
cancer treatment. Inhibition of proteasome function leads
to the accumulation of polyubiquitinated proteins and likely
causes the accumulation of misfolded proteins in the ER
due to the blockage of ER-associated degradation. Thus,
proteasome inhibitors activate autophagy via ER stress.
Proteasome inhibitors have been potent anticancer agents
for various cancers. Proteasome inhibitor MG-132 increased
the protein expression of LC3-I and -II in a time-dependent
manner. 3-MA signiﬁcantly abolished the formation of
LC3+ autophagic vacuoles and the expression of LC3-II,
but not LC3-I, induced by MG-132 [75] .An e wc l a s so f
proteasome inhibitors such as glidobactin A treatment also
induced autophagy as judged by the presence of the lipidated
form of LC3 and autophagosomes [76]. The eukaryotic 20S
proteasomecontainsthreecatalyticsubunits(β1,β2,andβ5)
conferring caspase-like, trypsin-like, and chymotrypsin-like
proteolytic activities, respectively. Glidobactin A blocked the
chymotrypsin-likeactivityirreversiblyatlowconcentrations,
whereas the trypsin-like activity was less sensitive and the
caspase-like activity was not inhibited at the concentrations
tested (up to 20μM).
9.2. AntiAutophagics (Table 2)
9.2.1. Atg Proteins. The regulation of the autophagic and
apoptotic response has been shown to require components
that are involved in both processes. Caspases,af a m i l yo f
cystinyl aspartate-requiring proteases, play a central role
in apoptosis, a well-studied pathway of programmed cell
death. Calpain is a calcium-dependent intracellular cysteine
protease that plays a crucial role in the regulation of cell
spreading, cell migration, programmed cell death, and cell
cycle progression. The majority of human Atg proteins can
be cleaved by caspases and calpains, which are activated
in some apoptotic paradigms [77]. For example, Atg3 is
cleaved by caspase-3,- 6, and -8, while Atg9, Atg7, and Atg4
homologues can be cleaved by caspase-3. Beclin 1 (Atg6) is
as u b s t r a t eo fcaspase-3 with two cleavage sites at positions
124 and 149, respectively. Cleavage of Beclin 1 was also seen
in apoptosis of HeLa cells induced by staurosporine and
TRAIL. The cleavage of Beclin 1 resulted in abrogation of
the interaction between Bcl-2 with Beclin 1, which could
be blocked by z-VAD-fmk. Atg5 is a gene product required
for the formation of autophagosomes. Calpains-1 and -
2 activation and Atg5 cleavage are general phenomena in
apoptotic cells. Truncated Atg5 translocated from the cytosol
to mitochondria, associated with the antiapoptotic molecule
Bcl-xL, and triggered cytochrome c release and caspase
activation. Caspase cleavage of autophagy-related proteins
can aﬀect the autophagic process.
9.2.2. Autophagosome Formation. Verteporﬁn (visudyne) is
a benzoporphyrin derivative used in photodynamic ther-
apy, and verteporﬁn inhibited drug- and starvation-induced
autophagicdegradationandthesequestrationofcytoplasmic
materials into autophagosomes [78]. Verteporﬁn inhibited
autophagy stimulated by serum starvation, a physiological
stimulus, and by rapamycin, the chemical inhibitor of
mTORC1. Verteporﬁn binds to the membrane of expanding
phagophoresortoafactorinvolvedinphagophoreexpansion
and prevents expanding phagophores from adopting their
characteristic cup shape, so they are unable to capture
cytoplasmic cargo and only form empty single-membrane
vesicles. 3-Methyladenine (3-MA), as an autophagy inhibitor,
was ﬁrst discovered via screening of purine-related sub-
stances using isolated hepatocytes from starved rats. 3-MA,
which interferes with the formation of autophagosomes
in mammalian cells via inhibition of the class III PI3K
activity that controls the autophagic pathway [79], has been
widely used in studies on autophagy. 3-MA has a dual
role in modulation of autophagy; although it is capable of
suppressing autophagy induced by starvation, its prolonged
treatment in full medium induces autophagy. Under speciﬁc
treatment conditions, 3-MA acts similar to rapamycin,
a well-established autophagy inducer via suppression of
mTOR function.
9.2.3. Bcl-2 Family. Apoptosis and autophagy are both
closely regulated biological processes that play a central role
in tissue homeostasis, development, and disease. The anti-
apoptotic protein Bcl-2 functions not only as an antiapop-
totic protein but also as an anti-autophagy protein via its
inhibitory interaction with Beclin 1 [80]. Beclin 1 functions
in the lysosomal degradation pathway of autophagy and
inducesautophagiccelldeathincancercells.Bcl-2/Bcl-xLcan
bind Beclin 1 and inhibit Beclin 1-dependent autophagic cell
death in cancer cells. The BH3 domain of Beclin 1 also bindsInternational Journal of Cell Biology 9
Table 2: Antiautophagics.
Class (target) Compounds Antiautophagic mechanisms Reference
Atg proteins Calpain-1, -2
Caspase-3, -6, -8 Defect in autophagic process and apoptotic enhancement [77]
Autophagosome
formation
Verteporﬁn
3-Methyladenine
Inhibition of autophagic degradation
Inhibition of class III PI3K activity
[78]
[79]
Bcl-2 family Bcl-2/Bcl-xL Inhibitory interaction with Beclin 1 [80]
[41]
Beclin 1 Metformin Decrease in Beclin 1 expression and AMPK activation [81]
Chemokines CCL2 Survivin upregulation [82]
Golgi-associated agents Monensin
Nocodazole
Dilatation of Golgi apparatus
Disconnection of Golgi stacks and dispersal into fragments
[83]
[84]
Heat shock proteins Geldanamycin
PES
Promotion of Beclin 1 degradation
Impairment of the autophagy-lysosome system
[85]
[86]
Lysosomal function
Baﬁlomycin A1
Lucanthone
Chloroquine
Prevention of fusion of autophagosomes with lysosomes
Lysosomal membrane permeabilization
Blocking of lysosyme acidiﬁcation
[87]
[88]
[89]
Small regulatory RNAs
Beclin 1
Lamp-2
mi-30a
Potentiation of apoptotic death, autophagosome degradation
Impairment of autolysosome formation
Beclin 1 translational suppression
[90]
[91]
[92]
to the BH3 binding groove of Bcl-xL. When the BH3 binding
groove of Bcl-xL is mutated, the interaction between Bcl-
xL and Beclin 1 is disrupted. Furthermore, the interaction
between Beclin 1 and Bcl-xL can be inhibited by ABT737 at
low doses, which stimulates autophagy without inducing cell
apoptosis. A novel Bcl-xL inhibitor, Z36, eﬃciently induces
autophagic cell death in HeLa cells. Z36 can competitively
inhibit the interaction between Bcl-xL and Beclin 1 in vitro,
and thus it is likely that Z36 induces autophagy by blocking
the interaction between Bcl-xL/Bcl-2 a n dB e c l i n1[ 41]. Bcl-
2 phosphorylation resulted in increased dissociation of the
Bcl-2-Beclin 1 complex and increased Beclin 1-dependent
autophagy. The activation of JNK upregulated Beclin 1
expression and mediated Bcl-2 phosphorylation, thereby
promoting cellular survival.
9.2.4. Beclin 1. Metformin, a widely used antidiabetic agent,
should potentially induce autophagy as an activator of
AMPK and an inhibitor of mTOR. Metformin’s action
is mainly mediated by AMPK activation. 2-Deoxyglucose
(2DG) is an inhibitor of glucose metabolism, since it
inhibits hexokinase, the ﬁrst rate-limiting enzyme of gly-
colysis. Treatment with 2DG leads to intracellular ATP
depletion and induces autophagy in prostate cancer cells.
Metformin inhibits 2DG-induced autophagy, reduces Beclin
1 expression, and triggers a switch from a survival process
to cell death [81], suggesting that, depending on cell type,
activation of AMPK is not automatically associated with the
induction of autophagy.
9.2.5. Chemokines. The CC chemokine, CCL2 (MCP-1), is
one of the most frequently observed chemokines in the
microenvironment of tumors. CCL2 has been demonstrated
to play a signiﬁcant role in prostate cancer neoplasia and
invasion. CCL2 protects prostate cancer PC3 cells from
autophagic death via the PI3K/Akt/survivin pathway and
showed survivin to be a critical molecule in this survival
mechanism[82].CCL2stimulationofPC3cells,uponserum
deprivation, results in Akt hyperphosphorylation of the two
k e yr e g u l a t o r ys i t e s( S e r 473 and Thr308) required for its full
activation. Survivin is a 16.5-kDa protein that belongs to the
inhibitor of apoptosis protein (IAP) family that functions
in mitotic progression and antagonizes caspases, thereby
inhibiting apoptosis. Survivin is highly expressed in cancer
tissues and its high level of expression is associated with
poor prognosis and survival in many cancer types. CCL2-
mediated survivin upregulation was shown to be PI3K/Akt-
dependent; inhibition of this pathway not only abrogated
survivin expression but also dramatically reduced cell sur-
vival. Strong evidence for interaction between survivin and
LC3 was detected by co-immunoprecipitation experiments
[82]. As LC3 plays an important role in the formation and
expansion of autophagosomal membranes, the survivin-LC3
interaction could inhibit this process, which is then reﬂected
in changes in LC3 localization as observed when starved cells
are treated with CCL2.
9.2.6. Golgi-Associated Agents. Chemical inhibition of auto-
phagy by incubations with monensin (coban) signiﬁcantly
increases the extent of apoptosis, which takes place via the
mitochondrial pathway, and shortens the time in which
the apoptotic markers are detectable. Monensin causes an
accumulation of early forms of autophagic vacuoles and
blocks the swelling of lysosomes seen in the presence of
methylamine. Incubation with monensin at higher concen-
trations (10 and 100μM) resulted in severe mitochondrial
damage and marked dilatation of the Golgi apparatus and
rough ER cisternae [83]. Interruption of microtubules with
microtubule destabilizing nocodazole impairs the conversion
of LC3-I to LC3-II but does not block the degradation10 International Journal of Cell Biology
of LC3-II-associated autophagosomes. Strong inhibition of
autophagic vacuole accumulation was found in nocodazole-
arrested pseudoprometaphase cells. The loss of microtubules
induced by nocodazole treatment results in the disconnection
of Golgi stacks and dispersal into 70–100 smaller fragments
[84].
9.2.7. Heat Shock Proteins. Heat shock protein 90 (Hsp90)
forms a protein complex to maintain the stability of its
client proteins. Disruption of this protein complex with
speciﬁc Hsp90 inhibitors leads to proteolytic degradation
of the client proteins, usually through the ubiquitin-
proteasome pathway. Hsp90 forms a complex with Beclin
1 through an evolutionarily conserved domain to maintain
the stability of Beclin 1. Geldanamycin, an Hsp90 inhibitor,
eﬀectively promoted proteasomal degradation of Beclin 1
in a concentration-dependent and time-dependent manner
[85]. A small molecule called 2-phenylethynesulfonamide
(synonym, also called piﬁthrin-μ, PES) interacts selectively
with Hsp70 and leads to a disruption of the association
between Hsp70 and several of its cochaperones and substrate
proteins. PES was identiﬁed as a novel Hsp70 inhibitor. PES-
mediated inhibition of Hsp70 family proteins in tumor cells
results in impairment of the autophagy-lysosome system.
PES impaired the mitochondrial localization of p53 [86].
Thep14/p19ARF tumorsuppressorgeneisfrequentlymutated
in human cancer. ARF (alternative reading frame) has been
shown to localize to mitochondria and to induce autophagy.
Treatment of cells with PES blocks the traﬃcking of ARF to
mitochondria.
9.2.8. Lysosomal Function. Baﬁlomycin A1 is in the pleco-
macrolide subclass of macrolide antibiotics, and a highly
speciﬁc inhibitor of V-ATPase, whereas other types (F-
type, P-type, Ca2+,a n dK +) of ATPases are not aﬀected
by this antibiotic. The anticancer eﬀect of baﬁlomycin A1
is well known and is attributed mainly to the inhibition
of autophagy by preventing the fusion of autophagosomes
with dysfunctional lysosomes, consequently triggering apop-
tosis [87]. Lucanthone (miracil D) has been extensively
used as an antischistome agent. The drug also blocks
topoisomerase II activity and has been reported to inhibit
AP (apurinic/apyrimidinic) endonuclease, an important
enzyme in DNA base excision repair. Lucanthone inhibits
autophagy, caused by induction of lysosomal membrane
permeabilization. Lucanthone is a novel autophagic inhibitor
that induces apoptosis via cathepsin D accumulation. In
addition, lucanthone enhanced the anticancer activity of the
histone deacetylase inhibitor vorinostat [88]. Lucanthone is
currently being investigated as a sensitizer to chemotherapy
and radiation due to its ability to interfere with DNA repair.
Chloroquine (avloclor) is a well-known 4-aminoquinoline
class drug that is widely used for prophylaxis treatment
against malaria. Pharmacologically, chloroquine is a weak
base and is trapped in acidic organelles like lysosomes,
resulting in increased vacuolar pH6.0. Chloroquine and its
analog hydroxychloroquine (plaquenil) are the only clinically
relevant autophagy inhibitors that block lysosyme acidiﬁ-
cation and degradation of autophagosomes [89]. Chloro-
quine, through its lysosomotropic properties, as well as its
autophagy inhibition ability, may be a promising agent to
be used in combination with chemotherapeutic agents to
improve clinical results.
9.2.9. Small Regulatory RNAs. Small regulatory RNAs have
becomeaspeciﬁcandpowerfultooltoturnoﬀtheexpression
of target genes. Their actions include the suppression of
overexpressed oncogenes, retarding cell division by inter-
fering with cyclins and related genes or enhancing apop-
tosis by inhibiting anti-apoptotic genes. Paclitaxel, which
stabilizes microtubules and causes apoptosis, oﬀers both
symptomatic and survival beneﬁts for lung adenocarci-
noma. Both autophagy and apoptosis are induced in cancer
cells during the course of paclitaxel treatment. Paclitaxel
treatment could lead to the formation of acidic vesicular
organelles and the induction of Atg5, Beclin 1, and LC3
expression. Paclitaxel-mediated apoptotic cell death was
further potentiated by pretreatment with Beclin 1 siRNA
[90]. Lysosomal-associated membrane protein 2 (Lamp-2)
is a ubiquitous lysosomal membrane protein that is highly
expressed in normal human pancreatic tissue and is required
for the proper fusion of lysosomes with autophagosomes
in the late stage of the autophagic process. Silencing with
as p e c i ﬁ cLamp-2 siRNA abolished immunoﬂuorescence
particles for Lamp-2, conﬁrming depletion of Lamp-2
protein. LC3-positive immunoﬂuorescence puncta signiﬁ-
cantly increased in Lamp-2-silenced cells, suggesting that
Lamp-2 depletion correlated with the accumulation of
autophagosomes and a relative paucity of autolysosomes in
pancreatic acinar cells. Lamp-2 depletion causes a “traﬃc
jam” that culminates in the accumulation of autophago-
somes [91]. MicroRNAs (miRNAs) are a class of endoge-
nous, 22–24 nucleotide RNA molecules with the ability
to induce mRNA degradation, translational repression, or
both, via pairing with partially complementary sites in
the 3  UTR of the targeted genes. miRNAs can control
the expression of autophagic genes, thereby modulating
autophagic activity. Indeed, inhibition of the expression by
beclin 1 miR-30a leads to suppression of autophagic activity
[92].
10. Technical Errorsin Autophagy Study
One of the technical problems in the study of autophagy
is the lack of convenient and reliable methods to detect
it. Uncertainty in the conﬁrmation of the fully functional
autophagic process could be one of the causes of confusion
related to the role of autophagy in cell death. These
types of confusion and diﬃculties are more pronounced
in animal experiments that are critical in the study of
cancers. LC3 is now widely used to monitor autophagy.
One approach is to detect LC3 conversion (LC3-I to LC3-
II) by immunoblot analysis because the amount of LC3-
II is clearly correlated with the number of autophago-
somes. Despite a higher molecular weight than LC3-I,International Journal of Cell Biology 11
LC3-II migrates more rapidly in SDS-PAGE compared to
LC3-I, likely due to its higher hydrophobicity associated
with the phosphatidylethanolamine group. However, LC3-
II itself is degraded by autophagy, making interpretation of
LC3 immunoblotting results problematic. Furthermore, the
amount of LC3 at a certain time point does not indicate
autophagic ﬂux. Monitoring of the natural autophagic
substrate p62 (also called sequestosome 1) has been widely
used to assess autophagic ﬂux. The degradation of GFP-
LC3 was clearly less sensitive for inducers and activators of
autophagythanGFP-p62[93].Areductionintheabundance
of p62 due to its sequestration into autophagosomes, which
results from the direct molecular interaction between LC3
and the LC3 interacting motifs (LIR) of p62, a 22-amino-
acid acidic peptide motif, is interpreted as a sign of increased
autophagy [94]; however, endogenous p62 is not produced
at a constant level because some cellular stress conditions
lead to induction of p62 at the transcriptional level, meaning
that the level of p62 proteins is not solely determined by
its turnover. Earlier autophagy studies relied on cell staining
and ﬂuorescent microscopy. In particular, the overexpression
of GFP-LC3, in which GFP (green ﬂuorescent protein)
is expressed as a fusion protein at the amino terminus
of LC3, was widely used to measure autophagy. These
studies are limited, however, by several issues as follows:
incorporation into protein that aggregates independent of
autophagy, induction of autophagy by transfection proce-
dures, sensitivity of GFP-LC3 to acid pH, and cessation of
ﬂuorescence[95].GFPismoreresistantthanLC3inresponse
to lysosomal degradation. When analyzing autophagic ﬂux
based on GFP-LC3 degradation, the accumulation of free
GFP and GFP-LC3-II in the absence and presence of a lyso-
somal inhibitor should be compared. These may represent
a serious problem in experiments testing the autophagic
process.
Many compounds to regulate autophagy are limited by
the uncertainty as to whether they speciﬁcally target one step
of the autophagy process. It is of interest to compare relative
drug eﬀects obtained under diﬀerent settings, including
conditions, time points, and concentrations. The compound
3-MAhasbeentoutedasanautophagyinhibitorbutrequires
mM concentrations to inhibit class III PI3Ks involved
in autophagy. 3-MA not only arrests autophagy but also
prevents apoptosis by inhibiting the release of cytochrome
c and cathepsin B. Rapamycin, commonly applied to induce
autophagy, enhanced autophagy under full medium but had
a surprising inhibitory eﬀect under nutrient deprivation
conditions. Baﬁlomycin A1 is also commonly employed
to suppress autophagic ﬂux due to its inhibition of the
vacuolar type H+-ATPase (V-ATPase), blocking acidiﬁcation
of lysosomes and endosomes. However, long-term treatment
(>4h) of cells with baﬁlomycin A1 also interferes with the
traﬃcking of proteosomes, endosomes, and other cellular
processes [96]. Therefore, a need exists for chemicals that
target speciﬁc components of the autophagy machinery for
use as research tools, to address questions about autophagy
mechanisms and investigate the role of autophagy in
cancers.
11. Concluding Remarks
In this paper, the molecular players and mechanisms asso-
ciated with autophagy have been described. Although
autophagy is an important mechanism used by tumor cells
to tolerate metabolic stress and is involved in nearly all stages
oftumorigenesisandtumorprogression,theissueofwhether
autophagy is aimed primarily at cell survival or at cell death
is likely to remain a subject of debate for some time. As
autophagy is a dynamic process that is diﬃcult to measure
andquantify,newtechniquesforassessingautophagyneedto
be developed to ensure progress in this area of investigation.
The multifaceted nature of autophagy and its diverse cross-
talk with other biological processes must be carefully consid-
ered when the autophagic system is targeted for anticancer
beneﬁt.
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